linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth
ET Prime
R&D

Superbugs have designs on India. Our preparation is inadequate.

Anti-microbial resistance (AMR) is a threat that is growing in severity. The country needs to develop better tests for early diagnosis, educate patients and doctors to not overuse antibiotics, and invest in new-generation antibiotics. At the moment, it is doing too little in all three areas.
font size
FONT SIZE
save
SAVE
saved
SAVED
Gift this article
GIFT ARTICLE
anujgupta
29 Jun 2018 8 Mins Read 0 comment
Biofilm of antibiotic resistant bacteria, closeup view; Kateryna Kon/Shutterstock Shutterstock.com
Biofilm of antibiotic resistant bacteria, closeup view; Kateryna Kon/Shutterstock
Name of assassinSuperbug (drug-resistant pathogen) DescriptionA gang of super-adaptive bacteria, with exceptional abilities to communicate, evolve, and survive. Defence mechanismEvolutionary adaptation: what doesn’t kill a superbug makes it really strong. Mode of travel It uses air, water, soil, food or even a simple handshake to invade enemy territory (read humans). War strategyA
these combat plans? Going by the participation from the government and the private sector at present, the answer is a disappointing no. Perhaps non-profit organisations are doing their bit. Half of the new R&D projects targeting priority pathogens involve partnerships from primarily six organisations — Wellcome Trust, MMV, Bill & Melinda Gates Foundation, US NIH, BARDA, and TB Alliance.
Name of assassinSuperbug (drug-resistant pathogen) DescriptionA gang of super-adaptive bacteria, with exceptional abilities to communicate, evolve, and survive. Defence mechanismEvolutionary adaptation: what doesn’t kill a superbug makes it really strong. Mode of travel It uses air, water, soil, food or even a simple handshake to invade enemy territory (read humans). War strategyA these combat plans? Going by the participation from the government and the private sector at present, the answer is a disappointing no. Perhaps non-profit organisations are doing their bit. Half of the new R&D projects targeting priority pathogens involve partnerships from primarily six organisations — Wellcome Trust, MMV, Bill & Melinda Gates Foundation, US NIH, BARDA, and TB Alliance.

The latest from ET Prime is now on Telegram. To subscribe to our Telegram newsletter click here.

Gift this story

YOU CAN GIFT 0 MORE STORIES THIS MONTH

Maximum 10 Email IDs allowed

300 characters remaining

Gift Sent Successfully

Limit Reached
Limit Reached

You’ve gifted all the 0 articles from your monthly gift bucket!

Please come back next month.

0 more articles will be waiting for you in your gift bucket.

Current Edition

[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]